The DOI matches its Crossref record.
A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence
Abstract
Porcine gastric inhibitory polypeptide is a 43 amino acid residue polypeptide with the amino acid sequence Tyr–Ala–Glu–Gly–Thr–Phe–Ile–Ser–Asp–Tyr–Ser–Ile–Ala–Met–Asp–Lys–Ile–Arg–Gln–Gln–Asp–Phe–Val–Asn–Trp–Leu–Leu–Ala–Gln–Gln–Lys–Gly–Lys–Lys–Ser–Asp–Trp–Lys–His–Asn–Ile–Thr–Gln. Fifteen of the first 26 amino acids occur in the same position as they do in porcine glucagon, and nine of the first 26 in the same position as in porcine secretin. The calculated molecular weight of the polypeptide is 5105.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Sherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Discovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Mutt, V., & Said, S. I. (1974) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1974.tb03373.x · Cited by 414
Schwartz, C. J., Kimberg, D. V., Sheerin, H. E., Field, M., & Said, S. I. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107790 · Cited by 382
Hormone families: pancreatic hormones and homologous growth factors
Blundell, T. L., & Humbel, R. E. (1980) · Nature · doi:10.1038/287781a0 · Cited by 377
Characterization of rat hypothalamic growth hormone-releasing factor
Spiess, J., Rivier, J., & Vale, W. (1983) · Nature · doi:10.1038/303532a0 · Cited by 371
Endocrine Cells of the Gastric Mucosa
Solcia, E., Capella, C., Vassallo, G., & Buffa, R. (1975) · International Review of Cytology · doi:10.1016/s0074-7696(08)60982-1 · Cited by 339
Identification and Actions of Gastric Inhibitory Polypeptide
BROWN, J. C., DRYBURGH, J. R., ROSS, S. A., & DUPRÉ, J. (1975) · Proceedings of the 1974 Laurentian Hormone Conference · doi:10.1016/b978-0-12-571131-9.50017-7 · Cited by 333
Self-citationThe New Biology of Gastrointestinal Hormones
REHFELD, J. F. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.4.1087 · Cited by 329
Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315
“GIP was the first incretin isolated from the intestinal mucosa [5].”
BackgroundNeurohumoral, hormonal, and drug receptors for the lower esophageal sphincter
Goyal, R. K., & Rattan, S. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90304-9 · Cited by 297
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“Biological Characteristics Molecular weight 4984 g/mol 3298 g/mol [12,311] Secretion K-cells L-cells [33,34,311] Stimulus to secretion Glucose, fat Glucose, fat [40,312]”
BackgroundIntestinal Secretion: Stimulation by Peptides
Barbezat, G. O., & Grossman, M. I. (1971) · Science · doi:10.1126/science.174.4007.422 · Cited by 274
GIF biology and fat metabolism
Yip, R. G. C., & Wolfe, M. M. (1999) · Life Sciences · doi:10.1016/s0024-3205(99)00314-8 · Cited by 266
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“The first incretin hormone to be identified, glucose-dependent insulinotropic polypeptide (GIP), was purified from pig gut extracts 2 .”
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Tsukiyama, K., Yamada, Y., Yamada, C., Harada, N., Kawasaki, Y., Ogura, M., Bessho, K., Li, M., Amizuka, N., Sato, M., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0187 · Cited by 198
Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists
Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121
The Origin and Understanding of the Incretin Concept
Rehfeld, J. F. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00387 · Cited by 102
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
Meurot, C., Jacques, C., Martin, C., Sudre, L., Breton, J., Rattenbach, R., Bismuth, K., & Berenbaum, F. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.02.001 · Cited by 94
Incretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
Schauder, P., Brown, J. C., Frerichs, H., & Creutzfeldt, W. (1975) · Diabetologia · doi:10.1007/bf00429919 · Cited by 65
“GIP (lot 26-6-74 B and 30-4-75 G) was obtained as previously described [1, 2].”
BackgroundMethodSelf-citationGLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors
Tomkin, G. H. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i5.636 · Cited by 24
TURNER, D. S., ETHERIDGE, L., JONES, J., MARKS, V., MELDRUM, B., BLOOM, S. R., & BROWN, J. C. (1974) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1974.tb02820.x · Cited by 25
Self-citationEffects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
“The first of these, glucose-dependent insulinotropic polypeptide (GIP), was isolated in 1971 [2].”
Metadata
- Authors
- Brown, J. C., & Dryburgh, J. R.
- Venue
- Canadian Journal of Biochemistry
- Publisher
- Canadian Science Publishing
- Published
- 1971-08-01
- Volume
- 49
- Issue
- 8
- Pages
- 867-872
- ISSN
- 0008-4018 (ISSN-L)
- OpenAlex
- W1971990975
- Cited by
- 344
- References
- 0
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.nrcresearchpress.com/page/about/CorporateTextAndDataMining (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.